Amgen Inc. (NASDAQ:AMGN) Shares Sold by Teamwork Financial Advisors LLC

Teamwork Financial Advisors LLC cut its holdings in Amgen Inc. (NASDAQ:AMGN - Free Report) by 93.7% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,152 shares of the medical research company's stock after selling 31,953 shares during the quarter. Teamwork Financial Advisors LLC's holdings in Amgen were worth $671,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of AMGN. Capital World Investors increased its holdings in Amgen by 1,292.0% during the 4th quarter. Capital World Investors now owns 6,495,710 shares of the medical research company's stock valued at $1,693,042,000 after acquiring an additional 6,029,058 shares in the last quarter. Norges Bank purchased a new stake in Amgen during the 4th quarter worth about $1,541,991,000. GAMMA Investing LLC raised its stake in Amgen by 43,573.5% in the 1st quarter. GAMMA Investing LLC now owns 3,661,589 shares of the medical research company's stock valued at $1,140,768,000 after purchasing an additional 3,653,205 shares during the last quarter. Capital International Investors lifted its holdings in Amgen by 40.1% in the 4th quarter. Capital International Investors now owns 12,212,065 shares of the medical research company's stock valued at $3,182,843,000 after purchasing an additional 3,495,503 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its holdings in Amgen by 25.4% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 13,205,604 shares of the medical research company's stock valued at $3,441,909,000 after purchasing an additional 2,672,975 shares in the last quarter. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Amgen Stock Up 0.0%

NASDAQ:AMGN traded up $0.09 during trading hours on Thursday, hitting $287.10. The stock had a trading volume of 2,521,343 shares, compared to its average volume of 2,805,500. The company has a market cap of $154.38 billion, a PE ratio of 38.03, a price-to-earnings-growth ratio of 2.63 and a beta of 0.51. The business has a 50 day simple moving average of $282.39 and a two-hundred day simple moving average of $285.31. Amgen Inc. has a 1-year low of $253.30 and a 1-year high of $346.85. The company has a current ratio of 1.26, a quick ratio of 0.95 and a debt-to-equity ratio of 9.62.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its earnings results on Thursday, May 1st. The medical research company reported $4.90 earnings per share for the quarter, beating the consensus estimate of $4.18 by $0.72. Amgen had a net margin of 12.24% and a return on equity of 176.32%. The business had revenue of $8.15 billion during the quarter, compared to the consensus estimate of $8.05 billion. During the same period in the prior year, the firm earned $3.96 earnings per share. The business's quarterly revenue was up 9.4% compared to the same quarter last year. Analysts predict that Amgen Inc. will post 20.62 EPS for the current year.

Wall Street Analyst Weigh In

AMGN has been the subject of a number of analyst reports. Mizuho boosted their price objective on shares of Amgen from $235.00 to $280.00 and gave the company a "neutral" rating in a research report on Wednesday, May 7th. Guggenheim started coverage on Amgen in a research note on Tuesday, May 20th. They set a "neutral" rating and a $288.00 price target on the stock. UBS Group restated a "neutral" rating and set a $315.00 price objective (down previously from $319.00) on shares of Amgen in a report on Friday, May 2nd. Royal Bank of Canada dropped their target price on Amgen from $324.00 to $320.00 and set an "outperform" rating for the company in a research note on Friday, May 2nd. Finally, Piper Sandler decreased their price target on Amgen from $329.00 to $328.00 and set an "overweight" rating on the stock in a research note on Friday, May 16th. Two research analysts have rated the stock with a sell rating, twelve have given a hold rating, nine have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $309.22.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.